DexCom (DXCM), noted for its continuous glucose monitoring systems, has been regarded as a
strong growth stock in the bio-tech market, despite occasional underperformance compared to competition. Its holdings are robust enough to attract significant interest from
Mitsubishi UFJ Trust & Banking Corp and
Empowered Funds LLC. It has also recently experienced a slight downturn, but its
Over the Counter (OTC) CGMs have been cleared by the FDA, promising continued growth. Dexcom's
CGM system has partnered with Automated Insulin Delivery systems (AID) in the Netherlands and the share prices have shown sustained growth over a five-year horizon with a stunning 26% Compound Annual Growth Rate (CAGR). Dexcom improved its sales views, its stocks have weathered market challenges, and are posting very healthy profits. The forthcoming Dexcom G7 system, approved by FDA, is expected to continue driving future growth. DexCom reported
first quarter 2024 financial results and is scheduled to post its
Q4 earnings soon. Furthermore,
Morgan Stanley has trimmed DexCom's price target to $120.00, and there are expectations for a significant earnings beat in the upcoming Q4 reports.
Dexcom DXCM News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sun, 21 Jul 2024 18:42:49 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 4
